OG0-092 全真模擬試験 DEMO

問題5: Scenario: Vittronics Ltd.
Please read this scenario prior to answering the question
Vittronics Ltd. is a leading medical device manufacturer in the highly competitive market for Migraine
Headache Pain Management (MHPM) devices. These tiny wireless devices are implanted in the brain
and can deliver a precise electric shock when the wearable Pain Control Unit (PCU) detects an increase
in stress induced by the onset of a migraine headache.
This technology will be a breakthrough in the treatment of this condition, and several competitors are
striving to be the first to introduce a product into the market. However, all of them must demonstrate the
effectiveness and safety of their products in a set of clinical trials that will satisfy the regulatory
requirements of the countries in the target markets.
The Enterprise Architecture group at Vittronics has been engaged in an architecture development project
to create a Secure Private Immersive Collaborative Environment (SPICE) that will allow researchers at its
product development laboratories worldwide to share information about their independent clinical trials.
The Vittronics Enterprise Architecture group is a mature organization that has been utilizing TOGAF for
several years. They have recently upgraded to TOGAF 9. The Vittronics Architecture Development
Method (VADM) is strictly based on the TOGAF 9 Architecture Development Method (ADM) with
extensions required to support current good manufacturing practices and good laboratory practices in
their target markets.
The SPICE project team has now completed the Business, Information Systems, and Technology
Architecture phases and has produced a complete set of deliverables for each phase. Due to the highly
sensitive nature of the information that is managed in SPICE, special care was taken to ensure that each
architecture domain included an examination of the security and privacy issues that are relevant for each
domain. A corresponding SPICE Security Architecture has been defined.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture activity.
Refer to the Vittronics Ltd Scenario:
You are serving as the Lead Architect for the SPICE project team.
As required by TOGAF, the SPICE project team res completed a Business Transformation Readiness
Assessment in Phase A (Architecture Vision). In that assessment, it was determined that there are risks
associated with the adoption of the Immersive Collaborative Environment. Despite a clear expression of
the vision and the business need for utilizing SPICE to accelerate the clinical trials, the researchers have
been resisting the change because of concerns about safeguarding individually identifiable information
about the subjects who were participating in the trials.
You have been asked to recommend how this situation be managed in the implementation planning
phases.
Based on TOGAF 9, which of the following is the best answer?
A. You decide that in Phase E, the team creates an overall solutions strategy that can guide the Target
Architecture implementation and structure the Transition Architectures. You check that there is consensus
before proceeding.
B. You decide to return to Phase A, where the team should brainstorm a technical solution that mitigates
the residual risks presented by the privacy issue. Then, during Phase D, you will directthe team to
develop an Architecture Building Block to manage the security risks. After that, the team should select
Solution Building Blocks that mitigate all of the identified risks and revise the Requirements Impact
Statement to reflect the changes to the high-level solutions strategy and migration plan.
C. You decide that in Phase E, the team review the Business Transformation Readiness Assessment and
identify, classify, and mitigate the risks associated with the identified readiness factors. If the risks can be
satisfactorily mitigated, then you would continue to define a high-level solutions strategy that includes the
Transition Architectures needed to make the change culturally and technically feasible.
D. You decide that in Phase E, the team determines an approach to implementing an overall strategic
direction that will address and mitigate the risks identified.
正解: B